Seeking Alpha

EU OKs AstraZeneca diabetes drug

  • European regulators have approved AstraZeneca's (AZN) Xigduo treatment for Type 2 diabetes.
  • The authorization is the first for a drug that combines an SGLT2 inhibitor, which cuts the reabsorption of excess glucose, and metformin, a standard therapy. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector